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Background: Safety and toxicity data for nebulised tobramycin are mainly derived from use of the Pari LC® Plus nebuliser, yet many centres are
now using advanced nebulisers, such as the eFlow®.
Methods: Ten children (ages 2–16 years) receiving 300 mg TOBI® via eFlow® for clinical reasons participated. Serum tobramycin levels were
obtained 1 h post nebulisation. Nine provided samples for urinary NAG, and 10 underwent audiology.
Results: Tobramycin levels were N1 mg/L in 3 children (maximum 3.8, 2 children aged 2 years). Urine NAG/creatinine levels were raised
(N0.94 μmol/min/mmol) in 5 children, 1 of these had a tobramycin level of N1 mg/L. One patient had high frequency hearing loss.
Conclusion: Serum tobramycin levels over 1 mg/L can occur 1 h post 300 mg TOBI® delivered by eFlow®. Raised urinary NAG levels suggest
that some children may have some associated early renal toxicity.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Paediatric; TOBI; eFlow; Pseudomonas aeruginosa1. Introduction
Chronic Pseudomonas aeruginosa (Pa) infection in cystic
fibrosis (CF) patients is associated with progressive pulmonary
function decline and is a major clinical predictor of morbidity
and mortality. [1–3] Nebulised tobramycin, an anti-Pseudomo-
nal aminoglycoside antibiotic, theoretically achieves and
maintains therapeutic levels in the lungs whilst minimizing
systemic toxicity. [4,5] Nebulised tobramycin is used to
eradicate first isolations of Pa in order to delay or prevent
chronic infection, [6] and in patients chronically infected is
associated with an increase in pulmonary function, reduction in
sputum Pa density, improved weight gain and decreased
hospitalization [4–9].☆ The title has been presented as a poster at the 32nd European Cystic Fibrosis
Conference, 10–13th June 2009, Brest, France.
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doi:10.1016/j.jcf.2010.03.007High serum levels of tobramycin are associated with renal
and oto-toxicity. [10,11] Renal toxicity is caused by a direct
effect on the proximal tubule's lysosomal system. Serum
creatinine is a late marker of renal toxicity and urine NAG (N-
acetyl-beta-D-glucosaminidase) enzyme excretion is an early
indicator of renal injury and aminoglycoside related renal
toxicity. [12] High frequency hearing loss is associated with
total daily aminoglycoside dosing, length of aminoglycoside
course and repetition of courses [11].
The safety data for nebulised TOBI® are based on studies in
adults and children using the LC Plus® nebulisation system
[4,13–16].
Advanced nebulisation systems such as the Pari eFlow®
have been widely introduced in recent years to deliver nebulised
TOBI®. [17] These have a high delivery efficiency and are
favoured by the patients due to their time saving qualities [18].
Studies of TOBI® using conventional nebulisers demon-
strated similar pharmacokinetics for age and gender when
extrapolated to the paediatric population over 6 months of age.d by Elsevier B.V. All rights reserved.
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demonstrated similar mean 1 h serum levels following delivery
by eFlow® when compared to LC Plus®.[17] However, the
highest 1 h level was 3.9 mg/L for eFlow® compared to 2.7 for
LC Plus®. Measures of renal and oto-toxicity were not assessed
[17].
Renal function data using creatinine levels suggest no long
term problems associated with inhaled tobramycin. [4,13] There
is one reported case of audiological problems associated with
nebulised TOBI®, in an adolescent with renal failure [20].
The purpose of this study is to measure serum tobramycin
levels in paediatric patients 1 h after receiving TOBI® by
eFlow®, and to assess for any evidence of renal or oto-toxicity.
2. Methods
Eligible patients were under 18 years of age, had a
genetically confirmed diagnosis of cystic fibrosis, and were
receiving nebulised TOBI® via eFlow® for clinical reasons.
Blood samples (at least 2 mL) were obtained 1 h after
nebulised TOBI®. Subjects were not receiving an intravenous
tobramycin treatment course at the time of sampling. Tobra-
mycin concentrations in the serum were measured by using the
standard laboratory Fluorescence Polarisation Immunoassay.
Patient notes were reviewed to determine length of time on
nebulised TOBI® and length of time using eFlow® for their
TOBI® medication.
Samples for urinary NAG analysis were requested on the
same day. These samples were frozen and analysed by a
spectrophotometric method (PPR Diagnostics Ltd, London,
UK). [21] Results were expressed as NAG/creatinine ratio to
account for the differing concentrating ability of children, and to
allow comparison to previous data on adult NAG/Cr levels [21].
The normal NAG/Cr ratio for the adult reference range is stated
as 0.12–0.47 μmol/min/mmol [21].
A pure tone audiogram was performed within the trial period
and the results were compared to previous where available.Table 1
Results for each subject, length of time on TOBI®, length of time on eFlow®, serum
NAG/creatinine ratios, time since most recent iv antibiotics, current and previous au
Patient
code
Age Sex Time on
TOBI®
(months)
Time on
eFlow®
(months)
Time level
taken
(min)
Serum
level
(mg/L)
TOBICF1 16 F 72 12 65 b1
TOBICF2 14 F 14 17 65 b1
TOBICF4 12 F 97 29 63 b1
TOBICF5 2 F 13 13 68 1.2
TOBICF6 12 F 72 17 95 b1
TOBICF9 10 F 6 8 68 b1
TOBICF10 11 M 47 29 60 3.8
TOBICF11 12 M 52 27 65 b1
TOBICF12 13 M 12 8 60 b1
TOBICF13 2 M 19 17 61 1.1
*Represents patients with significantly raised urine NAG/Cr ratios as determined by
†Represents patient whose urine NAG was received late and tested 8 months after t
Drugs at most recent iv antibiotic treatment course: ce: iv ceftazidime; ci: oral ciprof
tobramycin.The study was approved by both the UK Medicines and
Healthcare products Regulatory Agency (MHRA) and the
Leeds East Ethics Committee.
3. Results
Thirteen patients met the eligibility criteria and were
consented to commence the trial. Two patients declined to
give blood samples and were excluded (Patient codes TOBICF7
and TOBICF8). One patient stopped TOBI® after consent and
was therefore also excluded (TOBICF3).
The age range of patients was 2–16 years with a mean age of
10.4 and a median age of 12 years. Nine subjects provided urine
samples for NAG.
Results are shown in Table 1. Three tobramycin levels were
elevated above 1 mg/L, two of which were in the smallest
children aged 2 years and one elevated tobramycin level was in
an 11 year old. The tobramycin levels were obtained from 60 to
95 (mean 67 min) minutes after completion of TOBI®
nebulisation.
Five patients had significantly elevated the NAG/Cr ratio
more than double the adult normal reference range. One of the
children aged 2 years (TOBICF5) had both an elevated
tobramycin level and high urine NAG/Cr ratio, and had not
received any intravenous antibiotics for the preceding 22 weeks.
The audiology results were all normal except one high
frequency hearing loss in a 14 year old girl (TOBICF2). As she
did not have previous audiology this was of unknown duration.
This patient had normal tobramycin levels but had abnormal
NAG results, and had previously received frequent courses of
intravenous antibiotics, most recently 4 weeks prior to the
urinary NAG/Cr sample.
4. Discussion
Although TOBI® is now increasingly delivered via eFlow®,
the prescribing information continues to specify the Paritobramycin levels, time taken after completion of TOBI® via eFlow®, urinary
diology reports.
NAG/Cr
(μmol/min/mmol)
Weeks since
last IVs
(drugs)
Audiology report Past
audiology
report
5.05* 0 (me,co) Normal Normal
119*† 4 (me,to) R ear: 6 hz; 65 8 hz; 75 N/A
L ear: 6 hz; 20 8 hz; 40
N/A 0 (ce,co) Normal Normal
3.72* 22 (ce,to) Normal N/A
1.2* 9 (me,to) Normal Normal
0.06 17 (ce,to) Normal N/A
0.09 9 (ci,to) Normal Normal
0.57 9 (ce,to) Normal Normal
9.6* 0 (ce,co) Normal N/A
0.47 17 (pi,co) Normal N/A
more than double the adult reference range of 0.47 μmol/min/mmol. [12,21]
he tobramycin level.
loxacin; co: iv colistin; me: iv meropenem; pi: iv piperacillin/tazobactam; to: iv
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Pharmacokinetic data of TOBI® via eFlow® in adults has only
recently been published and did not assess renal or oto-toxicity
[17].
Our data show that three paediatric patients had serum
tobramycin levels of N1 mg/L 1 h following TOBI® nebulised
by the eFlow®. The two youngest patients in the study, both
aged 2, had elevated levels. The highest measured level was
3.8 mg/L, which is higher than the highest 1 h level of 3.62 mg/
L seen in a study of 258 patients using the LC Plus® [15]. Taken
together with the recent adult data [17], this would suggest that
that higher peak serum tobramycin levels are likely in some
patients when TOBI® is nebulised by the eFlow®. Although
the measured levels appear considerably lower than the 12 mg/
L level commonly used to guide intravenous tobramycin use
[17], the available eFlow® data are from small studies and
thus further larger pharmacokinetic and safety studies are
recommended.
Five children had significantly abnormal urinary NAG/Cr
ratio. Urinary NAG rose significantly during intravenous
tobramycin or colomycin courses but returned to baseline at
follow-up a median of 7 weeks later [12]. The significantly
elevated urinary NAG/Cr ratio seen in subjects TOBICF1,
TOBICF2, and TOBICF12 may be explained by recent
intravenous antibiotics. However, the urinary NAG data
regarding TOBICF5 and TOBICF6 are more concerning,
particularly in the former case as there had been no intravenous
antibiotics for the preceding 22 weeks, and the tobramycin level
1 h after TOBI® via eFlow® had been elevated N1 mg/L. Ring
et al. demonstrated elevated urinary NAG associated with
gentamicin nebulised via conventional nebuliser in people with
CF. [23] Our data suggest that two subjects have early evidence
of aminoglycoside related renal toxicity which may be related to
the delivery of TOBI® by the eFlow®.
The pattern of high frequency hearing loss seen in one
patient is suggestive of aminoglycoside damage but other
causes cannot be excluded. The importance of performing
routine audiology screening for all CF patients who receive
either intravenous or nebulised aminoglycosides regularly is
demonstrated.
5. Conclusion
TOBI® is only licensed for patients of 6 years and older and
efficacy and safety studies have not been performed by the
manufacturer in patients under the age of 6. This pilot study has
found that serum tobramycin levels over 1 mg/L can occur in
children 1 h following 300 mg TOBI® delivered by eFlow®,
and urinary NAG measurement suggests that some children
may have associated early renal toxicity. Two out of the three
children with raised tobramycin levels were 2 years of age.
These are important safety data that need to be considered when
prescribing TOBI® to the paediatric population. We suggest
particular caution when co-prescribing nebulised and intrave-
nous tobramycin and in interpreting serum drug levels in
relation to the timing of intravenous and nebulised tobramycin
in this setting.Acknowledgements
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